Diversified Consumer Services
Company Overview of Yale University
Yale University is an independent research and educational institution that offers programs, departments, schools, centers, museums, and affiliated organizations. The university offers graduate and professional courses in art, architecture, divinity, drama, engineering, music, forestry and environmental studies, law, management, and medicine. Yale University was founded in 1701 and is based in New Haven, Connecticut.
206 Elm Street
New Haven, CT 06511-9992
Founded in 1701
Key Executives for Yale University
Vice President of New Haven and State Affairs
Vice President for Finance & Business Operations
Program Director of Center for Business and the Environment
Vice President for Global and Strategic Initiatives
Compensation as of Fiscal Year 2014.
Yale University Key Developments
Boehringer Ingelheim with Yale University Collaborate to Investigate Novel Immunotherapy Targets Across Several Therapeutic Areas
Jan 13 15
Boehringer Ingelheim announced collaboration with Yale University with the goal of researching novel therapeutic targets in the field of immune-modulation. Immune-modulation refers to a range of treatments aimed at harnessing a patient’s immune system to fight disease. Under the terms of the agreement, the research capabilities of Boehringer Ingelheim and Yale University will be brought together to identify new immune-modulatory agents for oncology, autoimmune and respiratory disorders. The company will provide research funding for a select number of projects and work closely with scientists at Yale University to advance this research. The company has an option to obtain an exclusive license for all of these programs under pre-agreed terms with Yale University.
Novogen Limited, CanTx Inc. and Yale University Receive Confirmation of Drug Product Cantrixil, Passing Final Test of Efficacy as Evidence of Potential to Improve Survival Prospects of Patients with Late-Stage Ovarian Cancer
Nov 6 14
Novogen Limited and its joint venture company, CanTx Inc., with Yale University, has received confirmation that its experimental drug product, Cantrixil, has passed its final pre-clinical test of efficacy as evidence of its potential to significantly improve the survival prospects of patients with late-stage ovarian cancer. Cantrixil is a construct of the cytotoxic anti-cancer drug candidate, TRX-E-002-1, in a cyclodextrin (sugar) ball. Cantrixil has been designed specifically to be injected into body cavities (peritoneal cavity, pleural cavity) to seek out and destroy cancer stem cells, the cells primarily responsible for the initiation of cancer, its spread, and its continued growth in the face of chemotherapy. Cantrixil is being developed as a first-line, second-line and salvage therapy for ovarian cancer, and for the treatment of the late-stage conditions, malignant ascites and malignant pleural effusion. The initial Phase 1 study is to be conducted in women with late-stage ovarian cancer that has become unresponsive to standard therapy. Cantrixil has already successfully passed an animal model of first-line therapy in ovarian cancer. A follow-up study then was conducted as a final challenge to test the product’s efficacy in an animal model of refractory ovarian cancer. That final test is an animal model developed in conjunction with CanTx that mimics the clinical situation seen in women whose ovarian cancer has become resistant to all forms of chemotherapy. To date, no drug, standard or experimental, has been shown to produce any lasting or meaningful inhibition of the growth of the cancer in this model. The animal model involves the injection of human ovarian cancer stem cells into the peritoneal cavity of mice where they attach to and grow on the various abdominal organs, just as they do in women. The tumors display the same appearance and range of cell types as found in their human counterparts. The mice then are treated with paclitaxel, the standard first-line chemotherapy used in ovarian cancer. The paclitaxel produces a temporary anti-cancer effect, followed by rapid tumor growth despite ongoing paclitaxel treatment. This rapid tumor growth of chemo-resistant cancer again mimics what happens in late-stage ovarian cancer in women.
Oxford Performance Materials and Yale University Announce Joint Research Program to Develop Innovative and Cost-Effective 3D Printed Biomedical Technologies and Applications
Oct 29 14
Oxford Performance Materials Inc. announced the commencement of an extensive joint research program with Yale University to develop innovative and cost-effective 3D printed biomedical technologies and applications. This initiative will add renowned clinical expertise to OPM's comprehensive platform for device development, made up of OPM's proprietary OXPEKK(R) formulation of the high performance polymer poly-ether-ketone-ketone (PEKK), the company's additive manufacturing process, and its streamlined regulatory framework. The Yale-OPM joint research program will consist of ten distinct projects, featuring seven Yale faculty members, exploring a range of biomedical applications for 3D printing and PEKK. Projects include the development of new PEKK-based cranial and facial devices that support direct tissue attachment and 3D printed PEKK prosthesis for rib replacement. Projects also include 3D printed PEKK devices that deliver therapeutics for improved vertebral fusion as well as devices that deliver antibiotics to combat the pressing burden of implant associated infections.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|